JP2020502121A - 肺高血圧症および他の肺障害の処置のための方法および組成物 - Google Patents

肺高血圧症および他の肺障害の処置のための方法および組成物 Download PDF

Info

Publication number
JP2020502121A
JP2020502121A JP2019531750A JP2019531750A JP2020502121A JP 2020502121 A JP2020502121 A JP 2020502121A JP 2019531750 A JP2019531750 A JP 2019531750A JP 2019531750 A JP2019531750 A JP 2019531750A JP 2020502121 A JP2020502121 A JP 2020502121A
Authority
JP
Japan
Prior art keywords
weight
vasodilator
based composition
carrier
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502121A5 (https=
Inventor
ウィアーズ、ジェフリー
ロメロ、アラン
スミス、ヒュー
カーティス、ロバート
フロスト、アダーニ
シュー、ジェン
シュリニワス、リバティ
ドノバン、マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respira Therapeutics Inc
Original Assignee
Respira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respira Therapeutics Inc filed Critical Respira Therapeutics Inc
Publication of JP2020502121A publication Critical patent/JP2020502121A/ja
Publication of JP2020502121A5 publication Critical patent/JP2020502121A5/ja
Priority to JP2022197348A priority Critical patent/JP2023036678A/ja
Priority to JP2025019782A priority patent/JP2025065408A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019531750A 2016-12-14 2017-12-14 肺高血圧症および他の肺障害の処置のための方法および組成物 Pending JP2020502121A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022197348A JP2023036678A (ja) 2016-12-14 2022-12-09 肺高血圧症および他の肺障害の処置のための方法および組成物
JP2025019782A JP2025065408A (ja) 2016-12-14 2025-02-10 肺高血圧症および他の肺障害の処置のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434185P 2016-12-14 2016-12-14
US62/434,185 2016-12-14
PCT/US2017/066519 WO2018112258A1 (en) 2016-12-14 2017-12-14 Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022197348A Division JP2023036678A (ja) 2016-12-14 2022-12-09 肺高血圧症および他の肺障害の処置のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020502121A true JP2020502121A (ja) 2020-01-23
JP2020502121A5 JP2020502121A5 (https=) 2021-01-28

Family

ID=60888760

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531750A Pending JP2020502121A (ja) 2016-12-14 2017-12-14 肺高血圧症および他の肺障害の処置のための方法および組成物
JP2022197348A Pending JP2023036678A (ja) 2016-12-14 2022-12-09 肺高血圧症および他の肺障害の処置のための方法および組成物
JP2025019782A Pending JP2025065408A (ja) 2016-12-14 2025-02-10 肺高血圧症および他の肺障害の処置のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022197348A Pending JP2023036678A (ja) 2016-12-14 2022-12-09 肺高血圧症および他の肺障害の処置のための方法および組成物
JP2025019782A Pending JP2025065408A (ja) 2016-12-14 2025-02-10 肺高血圧症および他の肺障害の処置のための方法および組成物

Country Status (10)

Country Link
US (5) US10912778B2 (https=)
EP (2) EP4620525A3 (https=)
JP (3) JP2020502121A (https=)
CN (1) CN110381951A (https=)
AU (3) AU2017378409A1 (https=)
BR (1) BR112019012251A2 (https=)
CA (1) CA3046025A1 (https=)
MX (1) MX2019006938A (https=)
RU (1) RU2019121646A (https=)
WO (1) WO2018112258A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526835A (ja) * 2020-05-28 2023-06-23 ソフトハレ エヌヴイ ウイルス性の疾患の治療方法
JP2023548307A (ja) * 2020-10-28 2023-11-16 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2024535001A (ja) * 2021-09-10 2024-09-26 ユストゥス－リービッヒ－ウニヴェルジテート・ギーセン 肺高血圧症におけるレスキュー治療及び必要に応じた治療のための吸入イロプロスト
US12478748B2 (en) 2020-03-31 2025-11-25 Invox Belgium Nv Aerosol delivery of at least two liquid compositions
JP7851643B2 (ja) 2021-09-10 2026-04-27 ユストゥス－リービッヒ－ウニヴェルジテート・ギーセン 肺高血圧症におけるレスキュー治療及び必要に応じた治療のための吸入イロプロスト

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
WO2018132371A2 (en) * 2017-01-10 2018-07-19 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
WO2020210707A1 (en) * 2019-04-10 2020-10-15 Mayo Foundation For Medical Education And Research Methods and materials for gender-dependent treatment of cardiovascular dysfunction
KR20220019027A (ko) * 2019-06-10 2022-02-15 레스피라 테라퓨틱스 인크. 담체-기반 제제 및 관련 방법
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CN121843699A (zh) * 2023-05-31 2026-04-10 瑞必治公司 肺动脉高压治疗方法
CN116687888A (zh) * 2023-06-02 2023-09-05 苏州易合医药有限公司 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503393A (ja) * 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｃｏｐｄ及び肺高血圧の治療方法
JP2009537246A (ja) * 2006-05-15 2009-10-29 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
WO2015089105A1 (en) * 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
US4883810A (en) 1976-08-17 1989-11-28 Burroughs Wellcome Co. Ethers
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3417638A1 (de) 1984-05-10 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1219609B1 (en) 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Aromatic nitrogenous six-membered ring compounds
NZ524572A (en) 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
WO2002079143A1 (en) 2001-03-28 2002-10-10 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
JP2008546786A (ja) 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
CA2641393C (en) 2006-02-03 2014-12-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
KR20160048222A (ko) 2007-12-17 2016-05-03 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
WO2009086470A2 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
KR20230085944A (ko) 2008-03-18 2023-06-14 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
WO2009115235A1 (en) 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
KR20170024165A (ko) 2009-06-26 2017-03-06 니뽄 신야쿠 가부시키가이샤 결정
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2480526A1 (en) 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
EP3108888B1 (en) * 2010-03-15 2020-02-12 United Therapeutics Corporation Treatment for pulmonary hypertension
WO2011137734A1 (en) 2010-05-03 2011-11-10 Tsh Biopharm Company, Limited Pharmaceutical composition and method for treating hypertension
EP2593452B1 (en) 2010-07-14 2017-01-18 Novartis AG Ip receptor agonist heterocyclic compounds
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
CN104853744B (zh) 2012-10-31 2018-01-19 维克多瑞有限责任公司 气溶胶化伊洛前列素的给药
EP3110484A4 (en) 2014-02-21 2018-02-14 Respira Therapeutics, Inc. Powder inhaler, system and methods
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503393A (ja) * 2003-08-22 2007-02-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｃｏｐｄ及び肺高血圧の治療方法
JP2009537246A (ja) * 2006-05-15 2009-10-29 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
WO2015089105A1 (en) * 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478748B2 (en) 2020-03-31 2025-11-25 Invox Belgium Nv Aerosol delivery of at least two liquid compositions
JP2023526835A (ja) * 2020-05-28 2023-06-23 ソフトハレ エヌヴイ ウイルス性の疾患の治療方法
JP7761592B2 (ja) 2020-05-28 2025-10-28 インヴォックス ベルジアム エヌヴイ ウイルス性の疾患の治療方法
JP2023548307A (ja) * 2020-10-28 2023-11-16 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2024535001A (ja) * 2021-09-10 2024-09-26 ユストゥス－リービッヒ－ウニヴェルジテート・ギーセン 肺高血圧症におけるレスキュー治療及び必要に応じた治療のための吸入イロプロスト
JP7851643B2 (ja) 2021-09-10 2026-04-27 ユストゥス－リービッヒ－ウニヴェルジテート・ギーセン 肺高血圧症におけるレスキュー治療及び必要に応じた治療のための吸入イロプロスト

Also Published As

Publication number Publication date
US11491160B2 (en) 2022-11-08
JP2025065408A (ja) 2025-04-17
US20220347183A1 (en) 2022-11-03
US20210205318A1 (en) 2021-07-08
JP2023036678A (ja) 2023-03-14
US11491161B2 (en) 2022-11-08
BR112019012251A2 (pt) 2019-11-05
AU2022256085A1 (en) 2022-11-17
US20200093830A1 (en) 2020-03-26
AU2025260006A1 (en) 2025-11-20
US20220079949A1 (en) 2022-03-17
CA3046025A1 (en) 2018-06-21
EP3554507A1 (en) 2019-10-23
CN110381951A (zh) 2019-10-25
US12263174B2 (en) 2025-04-01
US10912778B2 (en) 2021-02-09
US20250195531A1 (en) 2025-06-19
RU2019121646A3 (https=) 2021-03-17
RU2019121646A (ru) 2021-01-15
WO2018112258A1 (en) 2018-06-21
EP4620525A3 (en) 2025-12-03
MX2019006938A (es) 2019-09-06
AU2017378409A1 (en) 2019-07-04
EP4620525A2 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
US12263174B2 (en) Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US6433027B1 (en) Medicament compositions based on tiotropium bromide and formoterol fumarate
AU777827B2 (en) Aerosol formulations and devices for increasing libido in women via acute testosterone administration
US11471435B2 (en) Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
JP2019520361A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
KR101718372B1 (ko) 에어로졸 볼러스로서의 일로프로스트의 투여
JP2025122121A (ja) 肺線維症を処置するための方法及び組成物
US20200222412A1 (en) Methods and compositions for treating pulmonary hypertension
CN111818912A (zh) 用于通过肺部给药而治疗抑郁症的干粉氯胺酮组合物
US20100197719A1 (en) Medicament compositions containing anticholinergically-effective compounds and betamimetics
WO2025180172A1 (zh) 一种含sgc受体激动剂的吸入混悬液制剂及其用途
JP2025514305A (ja) 肺疾患を処置するための方法および組成物
CN121714543A (zh) 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途
KR20250169548A (ko) 분무 건조 트레프로스티닐 제형
MXPA05011141A (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221209

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230308

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230314

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230407

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241210